Serum Institute applies for emergency use for Covid-19 vaccine
SII on Monday said it has applied to Drugs Controller General of India (DCGI) for emergency use authorisation for its Covid-19 vaccine
New Delhi: Vaccine manufacturing company Serum Institute of India (SII) on Monday said it has applied to Drugs Controller General of India (DCGI) for emergency use authorisation for its Covid-19 vaccine Covishield.
The Pune-based company has collaborated with Oxford University and pharmaceutical company Astra Zeneca for making the vaccine and is conducting trials in India.
"As promised, before the end of 2020, @SerumInstIndia has applied for emergency use authorisation for the first made-in-India vaccine, Covishield," SII CEO Adar Poonawala said in a tweet.
He further said: "This will save countless lives, and I thank the Government of India and Sri @narendramodi ji for their invaluable support."